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Abstract
Aims/Hypothesis: Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene have been shown to display a
powerful association with type 2 diabetes. The aim of the present study was to evaluate metabolic alterations in
carriers of a common TCF7L2 risk variant.
Methods: Seventeen non-diabetic subjects carrying the T risk allele at the rs7903146 TCF7L2 locus and 24 subjects
carrying no risk allele were submitted to intravenous glucose tolerance test and euglycemic-hyperinsulinemic clamp.
Plasma samples were analysed for concentrations of 163 metabolites through targeted mass spectrometry.
Results: TCF7L2 risk allele carriers had a reduced first-phase insulin response and normal insulin sensitivity. Under
fasting conditions, carriers of TCF7L2 rs7903146 exhibited a non-significant increase of plasma sphingomyelins
(SMs), phosphatidylcholines (PCs) and lysophosphatidylcholines (lysoPCs) species. A significant genotype effect
was detected in response to challenge tests in 6 SMs (C16:0, C16:1, C18:0, C18:1, C24:0, C24:1), 5 hydroxy-SMs
(C14:1, C16:1, C22:1, C22:2, C24:1), 4 lysoPCs (C14:0, C16:0, C16:1, C17:0), 3 diacyl-PCs (C28:1, C36:6, C40:4)
and 4 long-chain acyl-alkyl-PCs (C40:2, C40:5, C44:5, C44:6).
Discussion: Plasma metabolomic profiling identified alterations of phospholipid metabolism in response to challenge
tests in subjects with TCF7L2 rs7903146 genotype. This may reflect a genotype-mediated link to early metabolic
abnormalities prior to the development of disturbed glucose tolerance.
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Introduction
Type 2 diabetes mellitus (T2D) is a multifactorial disease
resulting from a complex interaction between environment,
adverse health behaviour and genetic risk factors, which may
affect β-cell function and/or insulin resistance. Genome-wide
association studies including thousands of cases and controls
described an association of 56 single nucleotide
polymorphisms (SNPs) with T2D susceptibility [1]. The
contribution of most gene polymorphisms appears to be small.
However, certain loci have substantial impact on the risk of
T2D. Variants in the transcription factor 7-like 2 (TCF7L2) locus
at 10q25.2 have been identified as the strongest common
genetic risk factors for T2D in Caucasians [1,2]. TCF7L2 SNPs
primarily affect insulin secretion and hepatic insulin sensitivity
[3,4]. A reduced GLP-1-induced insulin secretion in response to
oral glucose was detected in TCF7L2 risk allele carriers
[3,5–7]. TCF7L2 SNPs were shown to affect GLP-1
responsiveness of β-cells [3,7], indicating an impaired incretin
effect as one of the factors contributing to decreased insulin
secretion in TCF7L2 risk allele carriers. Other studies
demonstrated that TCF7L2 has an important role for vital
functions in islet cells [8]. Recently, it has been shown that
tissue-specific alternative splicing patterns of TCF7L2 mRNA
variants determine insulin sensitivity of adipose tissue and are
involved in the regulation of hepatic gluconeogenesis [9–11].
However, the underlying molecular and cellular mechanisms
of progression of insulin secretion deficiency and other
potential metabolic alterations related to TCF7L2 SNPs are
incompletely understood.
Metabolomics approaches have been successfully used to
distinguish normal glucose tolerant probands and patients with
impaired glucose tolerance or T2D [12–15]. Previous work
focused mainly on the relationship of metabolomic alterations
and insulin resistance and results are consistent with effects
explained by impaired insulin action, such as diminished
plasma amino acids due to increased amino acid oxidation [12]
or inadequate suppression of lipolysis [16].
Prediction and prevention of T2D would benefit from a better
understanding of the pathophysiological mechanisms involved
in prediabetes and the identification of metabolic alterations
associated with diabetes risk in a state when glucose
homeostasis is still normal. Therefore, in the present study, we
recruited non-diabetic probands carrying the TCF7L2
polymorphism rs7903146 and compared fasting plasma
metabolite levels and changes in defined metabolite
concentrations in response to challenge tests.
Methods
Study participants
Forty-one male subjects of western European descent were
recruited from the population-based KORA (Cooperative Health
Research in the Region of Augsburg, southern Germany)
cohort [17]. All study participants gave written informed consent
and the study was approved by the Ethics Committee of the
Bavarian Medical Association. Eight participants were
homozygous (TT) and nine heterozygous (CT) carriers of the
TCF7L2 rs7903146 allele, and 24 participants carrying no risk
allele (CC) with similar age and BMI served as control subjects.
Genotyping of TCF7L2 was performed as described previously
[18].
39 subjects had normal glucose tolerance (75 g oral glucose
tolerance test [oGTT]), one control subject had disturbed
glucose tolerance and in one carrier of the TCF7L2 rs7903146
allele with normal fasting glucose and normal HbA1c, the 2 h-
glucose level was missing. Plasma samples from oGTT were
not available in many probands. Probands did not take any
medication known to affect insulin sensitivity or secretion.
Participants underwent standard procedures including physical
examination, assessment of medical history, measurement of
blood pressure, and anthropometric measurements of weight,
height and waist circumference. Neither the participant nor any
of the attending physicians or assistants conducting the
intravenous glucose tolerance test (ivGTT) and the euglycemic-
hyperinsulinemic (EH) clamp knew the genotype of the
probands at the time of the test procedure.
Metabolic challenge tests
All metabolic challenge tests were carried out between 8:00
and 9:00 a.m. after a 10 to 12 hour fasting period and after
baseline blood samples were obtained. Participants underwent
an intravenous glucose tolerance test (ivGTT) receiving an i.v.
bolus of 0.33 g glucose/kg body weight of a 50 % (vol/vol)
glucose solution within two minutes. Venous blood samples
from the opposite arm were obtained at 1, 3, 5, 10, 15, 25 and
35 minutes for determination of insulin and proinsulin
concentrations. The sample taken at 35 minutes (t35) was also
kept for metabolomics measurement. Subsequently, the EH
clamp was initiated by an insulin bolus followed by a
continuous insulin infusion (1.05 mIU/kg/hour of short-acting
human insulin) and a variable infusion of a 20 % glucose
infusion to maintain the plasma glucose concentration at 80
mg/dl for 120 minutes. Blood samples for determination of
plasma glucose were obtained at 6 minute intervals throughout
the clamp and measured using a bedside glucose analyser
(Super-GL Ambulance, HITADO, Möhnesee, Germany). 45 min
after steady state conditions were reached (about 3-4 hours
after the start of the ivGTT), venous blood samples were drawn
for metabolomics measurement (t240).
Laboratory measurements
All blood samples were immediately cooled to 4°C and
centrifuged at 3000 g for 10 min. Aliquots of plasma samples
were stored at -80°C until assayed. Plasma glucose levels
were assessed using the hexokinase method (GLU Flex, Dade
Behring, Marburg, Germany). Total cholesterol concentrations,
high-density lipoprotein (HDL) and low-density lipoprotein
(LDL) levels were measured with enzymatic methods (CHOD-
PAP, Dade Behring). Triglycerides were measured by an
enzymatic color test (GPO-PAP-method, TGL Flex, Dade
Behring). Serum creatinine concentrations were assessed with
a modified Jaffe test (Krea Flex, Dade Behring). High sensitive
C-reactive protein (hsCRP) was determined by IRMA (Dade
Behring). HbA1c was measured using the HPLC method.
Plasma proinsulin and insulin concentrations were quantified
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with ELISA Kits (LINCO research, St. Charles, USA) as
described recently [19,20]. Serum C-peptide was determined
with the radioimmunoassay from Radim Diagnostics (Pomezia,
Italy). Total levels of non-esterified free fatty acids (NEFAs)
were measured using the Wako NEFA-HR(2) test (Wako
Chemicals GmbH, Neuss, Germany).
Targeted Metabolomics
Plasma samples from three different time points were
subjected to metabolomics measurement (t0, fasting sample;
t35, post-ivGTT; t240, clamp-steady state). Metabolite
concentrations were determined using the targeted
metabolomics kit AbsoluteIDQTM p150 (Biocrates Life Sciences
AG, Innsbruck, Austria) applying mass spectrometric analysis
as described previously [21]. The metabolomics data set
contains hexose, 14 amino acids, free carnitine (C0), 40
acylcarnitines, hydroxylacylcarnitines and
dicarboxylacylcarnitines, 15 sphingomyelins, 77
phosphatidylcholines, and 15 lysophosphatidylcholines
(complete list of the analysed metabolites is shown in Table
S1). Potential plate effects were addressed by multiplying
metabolite concentrations by a metabolite- and plate-specific
correction factor. This factor was calculated as the geometric
mean of the six plate-specific geometric means of metabolite
concentrations divided by the respective plate-specific
geometric mean.
Furthermore, metabolites that did not meet one of the
following criteria were excluded: (1) The coefficient of variation
(CV) of metabolite concentrations in the five reference samples
was ≥ 0.25 for all of the plates; (2) Kendall's correlation p-value
was ≥ 0.1 for correlation between the sample and the reference
sample means of the different plates; (3) less than 30 %
concentration values were exactly zero for this metabolite. 37
metabolites were excluded, leaving 126 for analysis (Table S1).
In addition, 45 metabolite sums that were assumed to indicate
a certain metabolic state or process were calculated, as
proposed in the Biocrates MetaDisIDQTM kit manual.
Calculations and statistical analysis
The area under the curve (AUC) of plasma insulin during the
first phase of the ivGTT was calculated according to the
trapezoid method as 0.5*[0.5*c0(insulin) +c1(insulin+c3(insulin)
+c5(insulin)+c10(insulin)] with cx(insulin) denoting the insulin
concentration at x minutes after ivGTT. The AUC of the
second-phase insulin response (time points 10, 15, 25 and 35
minutes after the glucose challenge) and the glucose response
were calculated accordingly. First-phase insulin response
(FPIR) was calculated as the sum of the plasma insulin values
at time points 1 and 3 minutes. Clamp-derived insulin
sensitivity index (ISI) was calculated as glucose infusion rate
per kg body weight necessary to maintain euglycemia during
the last 45 minutes of the clamp steady state per unit of plasma
insulin concentration. Proinsulin conversion was estimated as
proinsulin divided by insulin concentration at the indicated time
points.
Differences in baseline anthropometric and clinical data
between the two genotype groups were assessed using Mann-
Whitney U tests. Distributions of the metabolite concentrations
and sums, henceforth referred to as metabolite traits, were
assessed using quantile-quantile-plots and most were
considered to be of log-normal shape. Consequently, log-
transformed metabolite traits were used for all models.
Genotype and challenge effects on metabolite traits were
investigated with linear mixed-effects models using the R
package nlme, version 3.1-103 [22]. Specifically, for each of
the metabolite traits, we included genotype, coded as 1 (risk
allele carriers) and 0 (non-carriers), corresponding to a
dominant genetic model, two measurement time indicators (t35
and t240, with fasting measurement as reference category) and
the interaction of these with genotype to also explore the
modification of challenge effects by genotype. As potential
confounders, mean-centered BMI, age, and the interactions of
both with measurement time, were included in all models, and
random intercepts were included per each measurement time
point. Restricted maximum likelihood estimation was used. P-
values of genotype main effects and of genotype x
measurement time interactions were subjected to correction for
multiple testing using the Benjamini-Hochberg procedure [23].
All calculations concerning metabolomics analysis were
performed using the statistical environment R, version 2.14.2.
Results
Baseline characteristics
The baseline characteristics of the probands are given in
Table 1. There were no statistically significant differences in
anthropometric parameters, age, family history of diabetes,
waist circumference, systolic and diastolic blood pressure,
plasma triglycerides, total cholesterol, LDL-cholesterol, HDL-
cholesterol, creatinine, CRP and HbA1c values between
TCF7L2 risk allele carriers and controls. Fasting glucose,
insulin, proinsulin, and C-peptide levels were also similar in
both study groups.
Genotype effects in the fasting state
Fasting results in β-oxidation of fatty acids and
gluconeogenesis from amino acids. As expected, we observed
high plasma concentrations of non-esterified fatty acids
(NEFAs), free short chain acylcarnitines (C2 and C3) and
gluconeogenic amino acids (sum of glycine and serine). The
sum of branched-chain amino acids (leucin, isoleucine, valine)
did not differ between study groups (Table 2 and Figure S1).
Higher levels of several sphingomyelins (SMs),
lysophosphatidylcholines (lysoPCs) and phosphatidylcholines
(PCs) were observed in rs7903146 risk allele carriers (Table 2).
After correction for multiple testing, there was no statistically
significant genotype effect on any metabolite concentration in
the fasting samples.
Insulin response to intravenous glucose and insulin
sensitivity
The plasma insulin levels at 1, 3 and 5 minutes after the
glucose injection and the first-phase insulin response (FPIR,
sum of 1 + 3 minutes) were significantly reduced in carriers of
the TCF7L2 risk allele compared to the control group (Figure
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1A, 1B), whereas no significant differences in the second-
phase insulin response were observed. There was a non-
significant tendency towards lower proinsulin concentrations
(Figure 1C) and increased proinsulin to insulin ratio in the
TCF7L2 risk group after intravenous glucose injection (Figure
1D). The AUC of plasma glucose in the early and the late
phase after the glucose bolus was similar in rs7903146 risk
allele carriers and controls. No differences were found for
insulin sensitivity as determined by insulin sensitivity index (ISI)
during the EH clamp (Figure 1E). There was no significant
difference in FPIR, second phase insulin response and insulin
sensitivity between homozygous (TT) and heterozygous (CT)
carriers of the TCF7L2 rs7903146 allele.
Genotype effects on metabolite changes induced by
ivGTT-EH clamp
Metabolite concentrations were determined 35 minutes after
glucose infusion (t35). Overall, 162 metabolite traits showed
ivGTT-induced changes (p < 0.05) in both risk allele carriers or
control subjects. For 17 metabolites, we observed a significant
genotype effect on challenge-induced changes in TCF7L2 risk
allele carriers compared to control subjects (Table 3). All
Table 1. Baseline characteristics of the study population.
 




height (cm) 179.7 (7.5), [180.0] 177.6 (6.3), [177.0] 0.58
weight (kg) 87.4 (8.9), [85.5] 85.3 (11.8), [84.5] 0.55
BMI (kg/m2) 27.1 (2.6), [26.9] 27.0 (2.7), [25.5] 0.74
waist circumference (cm) 99.8 (7.5), [100.5] 99.9 (9.6), [96.0] 0.75
age (years) 51 (10.4), [50.5] 58 (10.1), [60.0] 0.07
systolic blood pressure
(mmHg)
140 (18.2), [136] 142 (14.2), [140] 0.49
diastolic blood pressure
(mmHg)
83 (11.1), [83] 85 (10.8), [85] 0.57










124 (25.4), [123.0] 0.58







CRP (mg/dl) 0.30 (0.6), [0.1] 0.22 (0.2), [0.1] 0.70
TSH (µU/ml) 1.6 (0.8), [1.5] 1.9 (1.1), [2.0] 0.55
HbA1(c) (%) 5.5 (0.2), [5.6] 5.7 (0.3), [5.6] 0.29
Fasting glucose (mg/dl) 96.8 (9.7), [97.5] 97.9 (10.9), [100.0] 0.73
2 h glucose (oGTT) 94.4 (29.7), [94.0] 93.5 (28.5), [90.8] 0.99
Insulin (pmol/l) 45.9 (18.6), [43.2] 37.5 (22.0), [31.7] 0.57
Proinsulin (pmol/l) 3.9 (4.6), [2.3] 3.0 (2.6), [1.9] 0.30
C-peptide (ng/ml) 2.8 (1.6), [2.4] 2.5 (1.1), [2.0] 0.76
NEFAs (mmol/l) 0.6 (0.4), [0.5] 0.55 (0.3), [0.5] 0.47
Data are given as mean (standard deviation), [median]. Given are the crude p
values before correction for multiple testing.
doi: 10.1371/journal.pone.0078430.t001
differentially regulated plasma metabolites were phospholipids
with the most pronounced differences observed in SMs. A
significantly higher decline of metabolites (delta t35) was
observed in 10 out of 13 SM species as well as for the sum of
all SM (Figure 2A) and hydroxylated SM (SM-OH) species.
Similar to SM levels, delta t35 for the sum of all measured
lysoPC species (Figure 2C), saturated lysoPCs and of four out
of 14 individual lysoPC species was significantly higher in
TCF7/L2 risk allele carriers. Of 74 analysed PCs, only delta t35
of PC aa C28:1, PC aa C40:4 and PC ae C40:5 (Figure 2F)
was significantly higher in the TCF7L2 group. Adjustment for
fasting insulin or FPIR attenuated the results, suggesting that
some alterations in phospholipids are influenced by disturbed
insulin secretion (Table S2).
After the ivGTT, an EH clamp was performed inducing an
anabolic state with high insulin plasma levels and increased
uptake of glucose in peripheral organs. EH clamp was
Table 2. Selected metabolite concentrations (µmol/l) in the
fasting state in carriers of TCF7L2 rs7903146 (CT/TT
genotype) and non-risk allele carriers (CC genotype).
 




C0 (µmol/l) 36.6 (6.6) 42.2 (9.8) 0.079
C2 (µmol/l) 7.9 (4.1) 8.12 (2.6) 0.914
C3 (µmol/l) 0.43 (0.14) 0.53 (0.20) 0.046
C4 (µmol/l) 0.21 (0.12) 0.34 (0.43) 0.039
C10 (µmol/l) 0.38 (0.15) 0.59 (0.54) 0.046
Non-essential amino acids
(µmol/l)
1085.5 (186.5) 1226.6 (195.7) 0.018
Sum of glycine and serine
(µmol/l)
293.2 (60.3) 325.6 (55.3) 0.088
Branched-chain amino acids
(µmol/l)
515.6 (93.1) 550.1 (135.7) 0.177
Proline (µmol/l) 181.6 (39.9) 226.8 (57.8) 0.005
lysoPCs (µmol/l) 171.0 (52.2) 190.1 (38.2) 0.025
Saturated lysoPCs (µmol/l) 105.9 (24.1) 122.0 (21.7) 0.006
lysoPC a C14:0 (µmol/l) 6.2 (0.7) 6.6 (0.6) 0.032
lysoPC a C16:0 (µmol/l) 98.2 (23.4) 113.9 (21.4) 0.007
lysoPC a C20:4 (µmol/l) 6.5 (3.1) 7.44 (2.06) 0.021
PC ae C36:4 (µmol/l) 204.7 (47.6) 234.2 (59.2) 0.045
PC ae C38:4 (µmol/l) 13.7 (3.5) 15.0 (3.6) 0.029
PC ae C38:5 (µmol/l) 17.9 (4.7) 20.61 (5.2) 0.025
PC ae C40:5 (µmol/l) 3.2 (0.7) 3.5 (0.6) 0.038
PC ae C44:5(µmol/l) 1.6 (0.5) 1.9 (0.4) 0.008
PC ae C44:6(µmol/l) 1.0 (0.3) 1.2 (0.2) 0.030
SMs (µmol/l) 328.7 (57.8) 377.7 (100.9) 0.045
SM C (µmol/l) 284.5 (49.8) 327.5 (87.0) 0.045
Long SM-OH (µmol/l) 1.7 (0.4) 2.0 (0.7) 0.039
SM C16:0 (µmol/l) 121.5 (22.5) 141.6 (35.9) 0.023
SM-OH C22:1 (µmol/l) 17.4 (3.8) 20.0 (5.8) 0.049
SM-OH C24:1 (µmol/l) 1.7 (0.4) 2.0 (0.7) 0.039
Data are given as mean (standard deviation). Given are the crude p values before
correction for multiple testing. Abbreviation of metabolites are explained in Table
S1.
doi: 10.1371/journal.pone.0078430.t002
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accompanied by a significant increase in carnitine (C0) levels
in control subjects but not in TCF7L2 risk allele carriers and a
marked decrease of short-chain acylcarnitines (C2, C3) and
NEFAs levels in both groups (Figure S1). We observed a
significant genotype effect at time-point t240 versus t0 in 17
metabolite traits (Table 4). Fasting insulin as well as FPIR
modified genotype effects on metabolites (Table S3). The
decrease of 8 SM species and the sum of all SMs were more
pronounced in TCF7L2 risk allele carries and all but one SM-
OH (SM-OH C14:1) were significantly altered. The most
prominent down-regulation occurred in SM-OH C24:1 (Figure
2B). At t240, three lysoPC species (lysoPC a C16:0, lysoPC a
C16:1, lysoPC a C17:0), the sum of all lysoPCs (Figure 2C)
and the sum of saturated lysoPCs displayed a significant
stronger decline in the TCF7L2 compared to the control group.
Change in total PC levels was not different between genotype
groups (Figure 2E). However, 7 unsaturated PC species
decreased significantly stronger in the TCF7L2 group (PC aa
C36:6, PC aa C40:4, PC ae C40:2, PC ae C40:5, PC ae C44:5,
PC ae C44:6).
Discussion
Using a targeted metabolomics platform, we identified
alterations in sphingolipid, phosphatidylcholine and
lysophosphatidylcholine metabolism in subjects at potentially
increased risk for T2D defined by the presence of the
rs7903146 risk genotype. The most important finding is that
these differences were only observed after challenge tests and
were present in a state when all conventional markers of
glucose metabolism such as fasting and 2-h glucose in oGTT,
fasting insulin, proinsulin and insulin sensitivity were still in the
normal range.
Measurement of a large number of metabolites by targeted
metabolomics is a promising approach to identify and quantify
intermediate and endpoint compounds of metabolism related to
specific disorders. This method has recently been successfully
Figure 1.  Response to an intravenous glucose challenge and insulin sensitivity as assessed by an EH clamp.  (A) The
insulin response was impaired at 1 (p = 0.03), 3 (p = 0.01) and 5 (p = 0.01) minutes after glucose challenge in the TCF7L2 group
(CT/TT genotype) as compared to the control group (CC genotype). (B) The first phase insulin response (FPIR, sum of insulin
values at 1 and 3 minutes) was significantly lower in TCF7L2 risk allele carriers. (C) TCF7L2 risk allele carriers had non-significantly
lower proinsulin values after intravenous glucose challenge. (D) The proinsulin/insulin ratio was only slightly elevated in the TCF7L2
group. (E) ISI (insulin sensitivity index) displayed no significant difference in carriers of the TCF7L2 risk allele compared to controls.
Data are given as mean and standard error of the mean in A, C and D.
doi: 10.1371/journal.pone.0078430.g001
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used to define metabolomic signatures of cardiovascular
diseases, neurological disorders, obesity and diabetes mellitus
[15,24–27]. Our hypothesis was that metabolic alterations may
precede the development of glucose intolerance and that the
disturbed metabolic homeostasis may be detected by
differences in plasma metabolite concentrations. We chose to
analyse non-diabetic male subjects harbouring the high risk
allele TCF7L2 rs7903146 and compared them with age-, sex-
and BMI-matched controls. Considering that TCF7L2 is
involved in β-cell dysfunction including impaired insulin
secretion and disturbed incretin effects as well as an enhanced
rate of basal hepatic glucose production [3–7], changes of
subsets of metabolites may provide novel insights into
biochemical pathways involved in the development of T2D.
In our study we demonstrate the presence of impaired FPIR
and normal insulin sensitivity in carriers of the TCF7L2
rs7903146 allele. Our data confirm the finding that TCF7L2
polymorphism is associated with an intrinsic β-cell dysfunction
and/or a reduction of β-cell mass [4]. Incretins are thought to
partly mediate the impaired insulin secretion in patients with
TCF7L2 risk allele [28]. By challenge with intravenous glucose
we can exclude any impact of incretins on metabolite
concentrations in the present study. Marked differences in the
regulation of plasma phospholipids were observed in ivGTT
and EH clamp. A stronger reduction of plasma metabolite
levels in TCF7L2 risk allele carriers compared to controls was
observed for 8 SMs, 6 PCs and 3 lysoPCs (t0 versus t240).
This finding may be explained by slightly increased basal
metabolite levels at the starting point under fasting conditions
and a stronger clearance of SMs, PCs and lysoPCs in the
TCF7L2 group after glucose challenge and additional
stimulation with high insulin levels. The fact that significant
genotype effects were only observed in challenge tests may
explain why other studies have not identified the same
metabolite profiles in risk allele carriers [13,19].
The three major phospholipid groups (SMs, PCs, lysoPCs)
are important structural components of plasma lipoproteins and
cell membranes and are involved in regulation of cell function,
membrane protein trafficking and inflammation [29]. In human
plasma, PCs comprise about 60-70 %, SMs 10-20 % and
lysoPCs 10-20 % of the circulating phospholipids. Increased
plasma SM levels have been reported in subjects with
subclinical atherosclerosis [30], coronary heart disease [31],
obesity [32] and diabetes mellitus [13]. We did not detect
significantly increased fasting SM levels in TCF7L2 risk allele
carriers. The present study is the first investigating metabolic
Table 3. Metabolic traits with significant genotype effect in response to ivGTT (t0 versus t35).
 Challenge response (iv glucose) CC genotype Challenge response (iv glucose) CT/TT genotype Genotype effect
Metabolite β se p-value β se p-value β se p-value p-value (corrected)
Phosphatidycholines
PC aa C28:1 -0.13 0.11 2.40E-01 -0.6 0.13 1.40E-05 -0.47 0.17 7.30E-03 5.00E-02
PC aa C40:4 -0.05 0.08 5.60E-01 -0.48 0.10 8.40E-06 -0.43 0.13 1.80E-03 3.60E-02
PC ae C40:5 -0.1 0.10 4.90E-01 -0.84 0.18 1.10E-05 -0.74 0.24 2.70E-03 3.60E-02
Lysophosphatidylcholines
lysoPC a C14:0 0.39 0.15 1.30E-02 -0.42 0.18 2.60E-02 -0.81 0.25 1.60E-03 3.60E-02
lysoPC a C16:0 -0.04 0.12 7.50E-01 -0.64 0.15 3.40E-05 -0.60 0.19 2.60E-03 3.60E-02
lysoPC a C16:1 -0.07 0.07 3.60E-01 -0.47 0.09 1.40E-06 -0.40 0.12 1.20E-03 3.60E-02
lysoPC a C17:0 -0.04 0.12 7.60E-01 -0.57 0.14 1.40E-04 -0.53 0.19 6.10E-03 4.70E-02
lysoPCs -0.12 0.10 2.40E-01 -0.63 0.12 2.80E-06 -0.51 0.17 3.00E-03 3.60E-02
Saturated lysoPCs -0.03 0.12 8.10E-01 -0.65 0.15 3.20E-05 -0.62 0.20 2.20E-03 3.60E-02
Sphingomyelins
SM-OH C14:1 0.05 0.11 6.20E-01 -0.45 0.13 9.00E-04 -0.50 0.17 4.80E-03 3.90E-02
SM-OH C22:1 0.02 0.12 8.40E-01 -0.49 0.14 7.30E-04 -0.51 0.19 7.10E-03 5.00E-02
SM-OH C22:2 0.04 0.12 7.20E-01 -0.57 0.14 1.60E-04 -0.61 0.19 2.00E-03 3.60E-02
SM-OH C24:1 0.09 0.12 4.60E-01 -0.57 0.14 1.30E-04 -0.66 0.19 8.30E-04 3.60E-02
SM C16:0 0.06 0.15 7.00E-01 -0.64 0.18 5.70E-04 -0.70 0.24 4.30E-03 3.90E-02
SM C16:1 0.02 0.14 8.80E-01 -0.64 0.16 2.10E-04 -0.66 0.22 3.50E-03 3.60E-02
SM C18:0 0.00 0.12 9.90E-01 -0.57 0.15 2.10E-04 -0.57 0.19 4.70E-03 3.90E-02
SM C18:1 0.02 0.12 8.90E-01 -0.52 0.14 5.20E-04 -0.53 0.19 6.50E-03 4.80E-02
SM C24:0 0.05 0.13 6.80E-01 -0.61 0.16 2.70E-04 -0.67 0.21 2.60E-03 3.60E-02
SM C24:1 0.07 0.13 6.10E-01 -0.55 0.16 7.40E-04 -0.61 0.21 4.20E-03 3.90E-02
SMs 0.05 0.14 7.20E-01 -0.65 0.17 3.70E-04 -0.70 0.23 3.50E-03 3.60E-02
SM C 0.05 0.14 7.20E-01 -0.64 0.17 3.90E-04 -0.70 0.23 3.60E-03 3.60E-02
SM-OH 0.04 0.12 7.40E-01 -0.53 0.14 3.50E-04 -0.57 0.19 3.50E-03 3.60E-02
Long SMs 0.06 0.14 6.40E-01 -0.60 0.16 4.70E-04 -0.66 0.22 3.20E-03 3.60E-02
Long SM C 0.06 0.14 6.40E-01 -0.60 0.16 5.00E-04 -0.66 0.22 3.40E-03 3.60E-02
Long SM-OH 0.09 0.12 4.60E-01 -0.57 0.14 1.30E-04 -0.66 0.19 8.30E-04 3.60E-02
doi: 10.1371/journal.pone.0078430.t003
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signatures after challenge tests in subjects with defined genetic
risk for T2D. We observed a significant genotype effect in
almost all SMs, suggesting a general alteration in the synthesis
or breakdown of sphingolipid metabolism. Several studies
indicate a role for SMs in the development of T2D by
influencing insulin resistance as well as insulin secretion. In SM
synthetase knockout mouse models it has been shown that the
reduction of plasma membrane SMs increased insulin
sensitivity [33,34]. Another study reported a decreased insulin
secretion due to mitochondrial dysfunction as a consequence
of altered membrane SM and ceramide contents [35].
Furthermore, apoptosis of β-cells is partly dependent on the
action of sphingomyelinase degrading SMs to ceramide [36].
Inhibition of ceramide synthesis decreased β-cell apoptosis and
defective protein trafficking in β-cells exposed to lipotoxicity
[37]. Thus, ceramides derived from SM degradation may
contribute to lipotoxicity-mediated β-cell apoptosis and may
accelerate the observed reduction of FPIR in carriers of the
TCF7L2 risk genotype.
While plasma LDL- and HDL-cholesterol and triglyceride
levels were similar in all probands, significant genotype effects
were detected in long-chain lysoPCs (C16:0, C16:1, C17:0)
and long-chain PC species (PCs containing C28-C44). The
finding of a disturbed PC/lysoPC metabolism is in agreement
with results from previous studies describing that altered PC
and lysoPC plasma profiles are associated with T2D (increased
PC aa (16:0/18:2); decreased PC aa (16:0/18:0), decreased
PC aa (18:0/20:4), increased lysoPCs (C16:0, C18:0, C18:1,
C18:2, C20:4)) [13], increased lysoPCs (C14:0, C16:1, C18:1,
C20:5, C22:6) [38], impaired glucose tolerance (decreased
lysoPC C18:2) ) [14,39] and increased risk for T2D (decreased
PC ae (C34:3, C40:6, C42:5, C44:4, C44:5), increased PC aa
(C32:1, C36:1, C38:3, C40:5)) [14]. In addition, increased
levels of several lysoPCs were reported in subjects with obesity
and insulin resistance [40]. Here, we did not find significantly
increased basal lysoPC species in subjects at increased risk
for T2D, but detected significant alterations in the regulation of
PCs with fatty acid aliphatic tails between 36 and 44 carbons.
This has not been described before in prediabetes or T2D and
may indicate that in parallel with the modification of the long-
chain lysoPCs there is also a disturbed regulation of very-long-
chain PCs in risk subjects carrying the TCF7L2 risk allele.
LysoPCs are produced by the action of phospholipase A2
(PLA2) or lecithin cholesterol acyltransferase (LCAT) on PCs
and the activity of both enzymes is related with plasma lysoPC
concentrations. LysoPCs, e.g. produced by increased PC
Figure 2.  Metabolites displaying the highest differences between TCF7L2 risk genotype carriers and
controls.  Concentration of total plasma SM, lysoPC and PC levels and selected SM-, lysoPC-, and PC-species in the fasting state,
35 minutes after the intravenous glucose bolus (t35) and during the steady state of the EH clamp (t240). (A) A significantly higher
decease of total SM plasma levels was observed in TCF7L2 rs7903146 allele carriers (CT/TT genotype) at t35 (p=3.5E-03) and
t240 (p = 4.4E-03) compared to CC genotype carriers. (B) SM-OH C24:1 plasma levels displayed the strongest difference between
the genotype groups in delta t35 (p = 8.3E-04) and delta t240 (p = 5.4E-04). (C) Delta t35 and delta t240 of total lysoPC was
significantly different between the genotype groups (p = 3.0E-03 and p = 3.6E-03). (D) LysoPC a C16:0 presented higher delta t35
(p = 2.6E-03) and deltat240 (p = 7.9E-04) in the subjects carrying the TCF7L2 rs7903146 risk allele. (E) The sum of all PCs did not
present significant differences. (F) However, several PC species decreased significantly stronger in risk allele carriers. Delta t35 (p =
2.7E-03) and t240 (p = 4.2E-03) of PC ae C40:5 are given as a representative example. Data are given as mean and standard error
of the mean. * = p ≤ 0.05 after correction for multiple testing.
doi: 10.1371/journal.pone.0078430.g002
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hydrolysis during LDL oxidation, are strong pro-inflammatory
lipid mediators [38] and are related to various
pathophysiological conditions including endothelial dysfunction
[41] and acute coronary syndrome [42]. Treatment of diabetic
patients with metformin led to decreased lysoPC levels [43]
and in vitro inhibition of PLA2 prevented palmitic acid-induced
insulin resistance in L6 myotubes by reduced generation of
lysoPC [44]. In contrast to these results, other studies
demonstrated that lysoPCs stimulate glucose uptake in 3T3-L1
adipocytes by elevating glucose transporter type 4 levels at the
plasma membrane yielding to lower blood glucose levels in
normal and diabetic mice [45]. Treatment of cultured islet cells
with phospholipase increased lysoPC contents and insulin
secretion [46]. Thus, there may be positive and negative effects
of some lysoPC species on insulin resistance and β-cell
function. The significant genotype effects on lysoPCs
containing C16:0, C16:1 and C17:0 fatty acid chains, which
have been observed in the present study, may suggest an
increased proinflammatory and proatherogenic state in TCF7L2
risk allele carriers. The underlying molecular mechanism in the
regulation of circulating PC species remains unclear.
Our challenge tests revealed that changes in metabolic
profiles of TCF7L2 risk allele carriers are reversible.
Hyperinsulinemia in the EH-clamp was able to reduce the
differences between the study groups. Although we did not
observe any differences in basal glucose or insulin levels,
adjustment for fasting insulin and FPIR attenuated the
association of phospholipids in TCF7L2 risk carriers,
suggesting that some alterations in metabolic homeostasis are
dependent on disturbed insulin secretion, which can be
overridden by high insulin doses. The most important sites for
the action of insulin are liver, adipose tissue and muscle.
Insulin inhibits gluconeogenesis in the liver, promotes the
storage of glycogen and induces the cellular uptake of amino
acids and fatty acids to produce proteins and lipids. Under high
insulin concentrations there is a strong inhibition of lipolysis
(e.g. reduction of NEFAs). One possible explanation for the
decline of phospholipid species during the EH-clamp in
TCF7L2 risk allele carriers is that the high insulin
concentrations induce sphingomyelinase, down-regulate SM
synthase or induce PLA2/LCAT, leading to decreasing plasma
concentration of SMs, lysoPCs and PCs. The exact
Table 4. Metabolic traits with significant genotype effect in response to EH clamp (t0 versus t240).
 Challenge response (clamp) CC genotype Challenge response (clamp) CT/TT genotype Genotype effect
Metabolite β se p value β se p value β se p value p value (corrected)
Acylcarnitines
C0 0.66 0.14 1.10E-05 0.01 0.17 9.50E-01 -0.65 0.23 5.40E-03 3.80E-02
Phosphatidylcholines           
PC aa C36:6 -0.18 0.09 4.80E-02 -0.65 0.11 1.60E-07 -0.47 0.15 2.40E-03 3.80E-02
PC aa C40:4 -0.01 0.10 9.20E-01 -0.48 0.12 1.90E-04 -0.47 0.16 4.80E-03 3.80E-02
PC ae C40:2 -0.11 0.13 3.80E-01 -0.69 0.16 4.00E-05 -0.57 0.21 7.40E-03 4.70E-02
PC ae C40:5 0.02 0.18 9.10E-01 -0.84 0.22 2.80E-04 -0.86 0.29 4.20E-03 3.80E-02
PC ae C44:5 0.02 0.13 8.90E-01 -0.72 0.17 4.00E-05 -0.74 0.22 1.10E-03 2.70E-02
PC ae C44:6 -0.02 0.15 9.10E-01 -0.74 0.18 1.30E-04 -0.72 0.24 3.90E-03 3.80E-02
Lysophosphatidylcholines
lysoPC a C16:0 0.33 0.16 3.90E-02 -0.56 0.19 4.70E-03 -0.88 0.25 7.90E-04 2.20E-02
lysoPC a C16:1 0.09 0.11 4.30E-01 -0.47 0.14 9.20E-04 -0.55 0.18 2.80E-03 3.80E-02
lysoPC a C17:0 0.24 0.14 7.80E-02 -0.56 0.17 1.10E-03 -0.81 0.22 4.50E-04 2.20E-02
lysoPCs 0.06 0.15 6.80E-01 -0.66 0.18 4.80E-04 -0.72 0.24 3.60E-03 3.80E-02
Saturated lysoPCs 0.33 0.16 3.90E-02 -0.57 0.19 4.30E-03 -0.90 0.26 7.40E-04 2.20E-02
Sphingomyelins
SM-OH C16:1 0.00 0.12 9.90E-01 -0.52 0.14 4.50E-04 -0.52 0.19 6.90E-03 4.60E-02
SM-OH C22:1 0.04 0.13 7.50E-01 -0.62 0.16 1.90E-04 -0.66 0.21 2.30E-03 3.80E-02
SM-OH C22:2 0.13 0.13 3.30E-01 -0.62 0.16 2.20E-04 -0.75 0.21 7.00E-04 2.20E-02
SM-OH C24:1 0.10 0.13 4.60E-01 -0.68 0.16 7.80E-05 -0.78 0.21 5.40E-04 2.20E-02
SM C16:0 0.03 0.17 8.60E-01 -0.75 0.20 4.30E-04 -0.78 0.27 5.00E-03 3.80E-02
SM C16:1 -0.03 0.16 8.60E-01 -0.78 0.19 9.50E-05 -0.75 0.25 3.70E-03 3.80E-02
SM C18:1 0.04 0.14 7.70E-01 -0.6 0.17 5.80E-04 -0.64 0.22 4.90E-03 3.80E-02
SM C24:0 0.07 0.15 6.40E-01 -0.71 0.18 2.10E-04 -0.78 0.24 1.80E-03 3.70E-02
SMs 0.04 0.16 8.00E-01 -0.73 0.20 4.20E-04 -0.77 0.26 4.40E-03 3.80E-02
SM C 0.04 0.16 8.30E-01 -0.72 0.20 4.80E-04 -0.76 0.26 5.10E-03 3.80E-02
SM-OH 0.06 0.13 6.40E-01 -0.63 0.16 2.30E-04 -0.69 0.22 1.90E-03 3.70E-02
Long SMs 0.06 0.15 6.90E-01 -0.65 0.19 8.40E-04 -0.71 0.25 5.30E-03 3.80E-02
Long SM C 0.06 0.15 7.00E-01 -0.64 0.19 9.00E-04 -0.70 0.25 5.60E-03 3.90E-02
Long SM-OH 0.10 0.13 4.60E-01 -0.68 0.16 7.80E-05 -0.78 0.21 5.40E-04 2.20E-02
doi: 10.1371/journal.pone.0078430.t004
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mechanisms by which high insulin concentrations influence
phosholipid synthesis or degradation are incompletely
understood and require further experimental and clinical
studies.
In contrast to other studies indicating an association of
increased plasma levels of several amino acids with
prediabetes and T2D [14,27,47], we did not find significant
changes in plasma amino acids. Different amino acid
concentrations have been shown to be associated with insulin
resistance in obese patients [24,48]. One study reported that
elevated plasma levels of three branched-chain amino acids
(valine, leucine and isoleucine) and two aromatic amino acids
(tyrosine and phenylalanine) are correlated with future risk for
T2D [27]. In the present study we did not observe any
difference in amino acid levels, which may be explained by the
fact that our study population was not obese and had normal
insulin sensitivity. In addition, only some probands carrying the
risk allele may progress to overt T2D. It may be speculated that
changes in amino acids occur at a late stage during the
development of T2D [39].
Limitations of the present study are the moderate sample
size, the lack of prospective follow-up investigation and the
complex interaction between the components of glucose, lipid
and protein metabolism, which may limit the interpretation of
the results. It is obvious that our findings need to be confirmed
in other independent populations. We are not able to make any
causal statements on the role of metabolic profiles on future
development of T2D. We used a targeted approach focussing
mainly on lipids. Thus, we cannot exclude associations
between TCF7L2 genotype and other metabolic products of
carbohydrate or protein metabolism, e.g. metabolites from the
tricarboxylic acid cycle. In addition, the exact biochemical
mechanisms leading to changes of these metabolites remain
unknown and the clarification of the biological significance of
these findings requires further investigation.
In conclusion, this study provides evidence for a complex
perturbation of phospholipid metabolism possibly linked to early
β-cell dysfunction in TCF7L2 risk allele carriers, in a state when
conventional parameters of glucose homeostasis are not yet
affected. Our findings suggest subtle modifications in the
regulation of intermediate metabolism, which can only be
detected by metabolic challenge tests. These data may
contribute to a better understanding of the biochemical
networks underlying the development of T2D in subject with the
TCF7L2 risk genotype.
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test. (B) The increase of C0 plasma levels was more
pronounced in the control group. (C) Plasma C2 decreased in
both groups in the EH clamp. (D) C4 levels were higher in the
fasting state in TCF7L2 risk allele carriers (CT/TT genotype),
which was not significant after correction for multiple testing.
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gluconeogenic amino acids serine and glycine decreased
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